If the U.S. Supreme Court agrees to tackle the long-simmering question of whether so-called “pay-for-delay” deals between drug companies violate antitrust law, it’ll likely be up to Williams & Connolly’s Kannon Shanmugam to establish that the deals pass muster.
On August 24, Shanmugam filed a petition for certiorari for Merck & Co., asking the court to review a July decision by the U.S. Court of Appeals for the Third Circuit that revived antitrust claims over Merck’s potassium-chloride supplement K-Dur. Shanmugam was joined on the petition by lawyers from his firm, Covington & Burling, McCarter & English and Baker Botts.
